Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Arcturus Therapeutics logo — A messenger RNA medicines company focused on the development...

Arcturus Therapeutics

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics

Founded 2013 United States San Diego, United States 155 employees Grant Total: $489.58M Biotechnology, Health Care +1

General Information

Company Name Arcturus Therapeutics
Founded Year 2013
Location United States San Diego, United States
Employees 155
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Arcturus Therapeutics. To contact Arcturus Therapeutics, visit arcturusrx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Arcturus Therapeutics compare?

A PDF of Arcturus Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Arcturus Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Arcturus Therapeutics

Arcturus Therapeutics is a global late-stage clinical messenger RNA medicines company based in San Diego, California. Founded in 2013, it operates in the Biotechnology and Health Care industries. Arcturus specializes in the development of mRNA medicines and vaccines, utilizing innovative technologies including LUNAR® lipid-mediated delivery and STARR® mRNA Technology (sa-mRNA). The company has garnered attention for its ongoing global collaboration with CSL Seqirus for innovative mRNA vaccines, and its joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus has a diverse pipeline including RNA therapeutic candidates aimed at treating ornithine transcarbamylase deficiency and cystic fibrosis, along with partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. The company's technologies are supported by an extensive patent portfolio with patents and patent applications issued in the U.S., Europe, Japan, China, and other countries. In its latest funding round, Arcturus Therapeutics secured a $9.00M Grant investment on 26 September 2023, with the Cystic Fibrosis Foundation participating as the investor. With its cutting-edge technology and diverse pipeline, Arcturus Therapeutics holds promise as a pioneering force in the field of mRNA therapeutics and vaccines.

Business keywords: mRNA medicines, vaccines, LUNAR® lipid-mediated delivery, STARR® mRNA Technology, mRNA drug substance, drug product manufacturing, RNA therapeutic candidates, mRNA vaccine programs, ornithine transcarbamylase deficiency, cystic fibrosis, nucleic acid medicines, patent portfolio, clinical trials, drug development

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $9.00M 1
Cystic Fibrosis Foundation
Cystic Fibrosis Foundation
26 Sep 2023
Grant $115.00M 1
Japan - The Government of Japan
Japan - The Government of Japan
14 Aug 2023
Grant $63.20M 1
Biomedical Advanced Research and Development Authority (BARDA)
31 Aug 2022
Post IPO Equity $200.00M -
28 Jul 2020
Post IPO Equity $80.50M -
15 Apr 2020
Grant $15.00M -
01 Aug 2019
Series A $5.00M -
21 Oct 2013
Seed Round $1.30M -
01 Jun 2013
Seed Round $580.00K -
05 Apr 2013

Arcturus Therapeutics Alternatives & Competitors

Arcturus Therapeutics vs
etherna
etherna Belgium

Enabling Nucleic Acid Medicines for Next‑Generation Therapies | www.etherna.be

Series B
97 employees
Biotechnology, Health Care
Compare Arcturus Therapeutics vs etherna
Arcturus Therapeutics vs
NanoVation Therapeutics™
NanoVation Therapeutics™ Canada

Delivering tomorrow's genetic medicines, today™

Grant
42 employees
Biotechnology, Health and Wellness

FAQ About Arcturus Therapeutics

A messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics
Arcturus Therapeutics was founded in 2013.
Arcturus Therapeutics is headquartered in San Diego, United States.
Arcturus Therapeutics operates in Biotechnology, Health Care and Health and Wellness. Its work centres on mRNA medicines, vaccines, LUNAR® lipid-mediated delivery and STARR® mRNA Technology.
Arcturus Therapeutics has approximately 155 employees.
Arcturus Therapeutics has completed 9 funding rounds, raising a total of $489.58M. The latest funding stage is Grant.
Top alternatives and competitors to Arcturus Therapeutics include etherna, NanoVation Therapeutics™. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Arcturus Therapeutics and etherna are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Arcturus Therapeutics, https://bouncewatch.com/company/arcturus-therapeutics, updated 9 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout